Lacking immunocytological GD2 expression in neuroblastoma: Report of three cases

Pediatric Blood and Cancer

Volumn 45, Issue 2, 2005, Pages 195-201

  Schumacher Kuckelkorn, Roswitha ^a   Hero, Barbara ^a   Ernestus, Karen ^a   Berthold, Frank ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

ch14.18 antibody treatment; GD2; Minimal residual disease (MRD); Neuroblastoma

Indexed keywords

ANTIBODY; GANGLIOSIDE GD2; MONOCLONAL ANTIBODY;

ARTICLE; CASE REPORT; CHILD; CONTROLLED STUDY; CYTOLOGY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROSCOPY; MINIMAL RESIDUAL DISEASE; NEUROBLASTOMA; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; BONE MARROW NEOPLASMS; CHILD; CHILD, PRESCHOOL; FALSE NEGATIVE REACTIONS; FEMALE; GANGLIOSIDES; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM, RESIDUAL; NEUROBLASTOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 22244449334     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20301     Document Type: Article

References (27)

1. Favrot MC, Frappaz D, Maritaz O, et al. Histological, cytological and immunological analyses are complementary for the detection of neuroblastoma cells in bone marrow. Br J Cancer 1986;54:637-641.
2. Cheung NK, Von Hoff DD, Strandjord SE, et al. Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies. J Clin Oncol 1986;4:363-369.
3. Oppedal BR, Storm-Mathisen I, Kemshead JT, et al. Bone marrow examination in neuroblastoma patients: A morphologic, immunocytochemical, and immunohistochemical study. Hum Pathol 1989;20:800-805.
4. Combaret V, Favrot MC, Kremens B, et al. Immunological detection of neuroblastoma cells in bone marrow harvested for autologous transplantation. Br J Cancer 1989;59:844-847.
5. Berthold F, Schneider A, Schumacher R, et al. Detection of minimal disease in bone marrow of neuroblastoma patients by immunofluorescence. Pediatr Hematol Oncol 1989;6:73-83.
6. Carey PJ, Thomas L, Buckle G, et al. Immunocytochemical examination of bone marrow in disseminated neuroblastoma. J Clin Pathol 1990;43:9-12.
7. Gussetis ES, Ebener U, Wehner S, et al. Immunological detection and definition of minimal residual neuroblastoma disease in bone marrow samples obtained during or after therapy. Eur J Cancer Clin Oncol 1989;25:1745-1753.
8. Moss TJ, Reynolds CP, Sather HN, et al. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 1991;324:219-226.
9. Faulkner LB, Tintori V, Tamburini A, et al. High sensitivity immunocytologic analysis of neuroblastoma cells in paired blood and marrow samples. J Hematother 1998;7:361-366.
10. Cheung NK, Heller G, Kushner BH, et al. Detection of neuroblastoma in bone marrow by immunocytology: Is a single marrow aspirate adequate? Med Pediatr Oncol 1999;32:84-87.
11. Nagai J, Ishida Y, Koga N, et al. A new sensitive and specific combination of CD81/CD56/CD45 monoclonal antibodies for detecting circulating neuroblastoma cells in peripheral blood using flow cytometry. J Pediatr Hematol Oncol 2000;22:20-26.
12. Cheung IY, Barber D, Cheung NK. Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers. Clin Cancer Res 1998;4:2801-2805.
13. Burchill SA, Lewis IJ, Selby P. Improved methods using the reverse transcriptase polymerase chain reaction to detect tumour cells. Br J Cancer 1999;79:971-977.
14. Shono K, Tajiri T, Fujii Y, et al. Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma. J Pediatr Surg 2000;35:1415-1420.
15. Burchill SA, Lewis IJ, Abrams KR, et al. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol 2001;19:1795-1801.
16. Fukuda M, Miyajima Y, Miyashita Y, et al. Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: A pilot study. J Pediatr Hematol Oncol 2001;23:10-13.
17. Trager C, Kogner P, Lindskog M, et al. Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastoma cells in blood and bone marrow. Clin Chem 2003;49:104-112.
18. Horibe K, Fukuda M, Miyajima Y, et al. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma. Med Pediatr Oncol 2001;36:203-204.
19. Mehes G, Luegmayr A, Koramuller R, et al. Detection of disseminated tumor cells in neuroblastoma: 3 log improvement in sensitivity by automatic immunofluorescence plus FISH (AIPF) analysis compared with classical bone marrow cytology. Am J Pathol 2003;163:393-399.
20. Zirbes TK, Lorenzen J, Baldus SE, et al. Apoptosis and expression of bcl-2 protein are inverse factors influencing tumour cell turnover in primary carcinoid tumours of the lung. Histopathology 1998; 33:123-128.
21. Berthold F, Hero B. Neuroblastoma: Current drug therapy recommendations as part of the total treatment approach. Drugs 2000;59:1261-1277.
22. Wu ZL, Schwartz E, Seeger R, et al. Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res 1986;46: 440-443.
23. Ladisch S, Wu ZL, Feig S, et al. Shedding of GD2 ganglioside by human neuroblastoma. Int J Cancer 1987;39:73-76.
24. Kramer K, Gerald WL, Kushner BH, et al. Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma. Clin Cancer Res 1998;4:2135-2139.
25. Kramer K, Gerald WL, Kushner BH, et al. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. Med Pediatr Oncol 2001;36:194-196.
26. Zippelius A, Kufer P, Honold G, et al. Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol 1997;15:2701-2708.
27. Ross AA. Minimal residual disease in solid tumor malignancies: A review. J Hematother 1998;7:9-18.